Combating HIV resistance - Focus on darunavir

Therapeutics and Clinical Risk Management

Volumn 4, Issue 4, 2008, Pages 759-765

  Tremblay, Cécile L ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antiretroviral therapy; HIV 1; Protease inhibitor; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A4; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; TIPRANAVIR; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING SITE; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG STRUCTURE; FOOD; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER TOXICITY; NAUSEA; PROTEINASE INHIBITION; REVIEW; RHINOPHARYNGITIS; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 52949132229     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Arasteh K, Clumeck N, Pozniak A, et al. 2005. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. Aids, 19:943-7.
2. Busse KH, Penzak SR. 2007. Darunavir: A second-generation protease inhibitor. Am J Health Syst Pharm, 64:1593-602.
3. Carter NJ, Keating GM. 2007. Maraviroc. Drugs, 67, 2277-88; discussion 2289-90.
4. Clotet B, Bellos N, Molina JM, et al. 2007. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet, 369:1169-78.
5. Clumeck N, Chiliade P, Clotet B, et al. 2007. ARTEMIS - Efficacy and Safety of Lopinavir (BID vs QD) and Darunavir (QD) in Antiretroviral-Naive Patients 11th European AIDS Conference. Madrid, Spain.
6. De Meyer S, Azijn H, Surleraux D, et al. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother, 49:2314-21.
7. De Meyer S, Lefebvre E, Azijn H, et al. 2006. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. 15th International HIV Drug Resistance Workshop. Sitges, Spain.
8. De Meyer S, Vangeneugden T, van Baelen B, et al. 2007. Effect of baseline and on-treatment mutations on the antiretroviral activity of darunavir/ritonavir (DRV/r) and lopinavir/ritonavir (LPV/r): results of a randomised, controlled, phase III study (TITAN). 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia.
9. De Meyer S, Vangeneugden T, Van Baelen B, et al. 2008. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses, 24:379-88.
10. Dejesus E, Ortiz R, Khanlou H. 2007. Efficacy and safety of darunavir/ ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at week 48: ARTEMIS. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, Illinois.
11. Delaugerre C, Mathez D, Peytavin G, et al. 2007. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. Aids, 21:1210-3.
12. [DHHS] US Department of Health and Human Services. 2008. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. In DHHS (Ed.).
13. Flexner C. 1999. HIV-protease inhibitors. N Engl J Med, 338:1291-92.
14. Ghosh AK, Chapsal BD, Weber IT, et al. 2007. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc Chem Res, 41:78-86.
15. Ghosh A K, Sridhar PR, Leshchenko S, et al. 2006. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J Med Chem, 49:5252-61.
16. Grinsztejn B, Nguyen BY, Katlama C, et al. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet, 369:1261-9.
17. Groeschen HM. 2007. Novel HIV treatment approved. Am J Health Syst Pharm, 64:1886.
18. Hall DB, Schapiro J, Boucher CAB, et al. 2007. Genotypic relationships between tipranavir and darunavir resistance in protease inhibitor experienced patients. 6th Intl HIV Drug Resistance Workshop. Barbados, West Indies.
19. Hammer SM, Saag MS, Schechter M, et al. 2006. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. Top HIV Med, 14:827-43.
20. Johnson VA, Brun-Vezinet F, Clotet B, et al. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med, 15:119-25.
21. Katlama C, Esposito R, Gatell JM, et al. 2007. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. Aids, 21:395-402.
22. King NM, Prabu-Jeyabalan M, Nalivaika EA, et al. 2004. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol, 78:12012-21.
23. Koh Y, Matsumi S, Das D, et al. 2007. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem, 39:28709-20.
24. Koh Y, Nakata H, Maeda K, et al. 2003. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother, 47:3123-9.
25. Kovalevsky AY, Liu F, Leshchenko S, et al. 2006a. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol, 363:161-73.
26. Kovalevsky AY, Tie Y, Liu F, et al. 2006b. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem, 49:1379-87.
27. Kuritzkes DR. 2007, HIV resistance: frequency, testing, mechanisms. Top HIV Med, 15:150-4.
28. Lazzarin A, Campbell T, Clotet B, et al. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 370:39-48.
29. Madruga JV, Berger D, McMurchie M, et al. 2007a. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet, 370:49-58.
30. Madruga JV, Cahn P, Grinsztejn B, et al. 2007b. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 370:29-38.
31. Mascolini M, Boucher C, Larder B, et al. 2007. Key reports from the XV International HIV Drug Resistance Workshop 2006. Antivir Ther, 12:131-45.
32. Molina JM, Cohen C, Katlama C, et al. 2007. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr, 46:24-31.
33. Picchio G. 2006. Analyses of susceptibility and cross-resistance between TMC114 and other protease inhibitors among >56,000 routine samples, using linear regression model-based fold change predictions. X-V International Drug Resistance Workshop. Sitges, Spain.
34. Poveda E, de Mendoza C, Martin-Carbonero L, et al. 2007. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother, 60:885-8.
35. Stephenson J 2007. Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus. JAMA, 297:1535-6.
36. Surleraux DL, Tahri A, Verschueren WG, et al. 2005. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem, 48:1813-22.
37. Tie Y, Kovalevsky AY, Boross P, et al. 2007. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins, 67:232-42.
38. Traynor K. 2007. Integrase inhibitor gains FDA approval. Am J Health Syst Pharm, 64:2310.
39. Vangeneugden. 2006. Impact of optimised background regimen on virological response to TMC114 with low-dose ritonavir in POWER 1, 2 and 3, as measured by the phenotypic susceptibility score. 15th International HIV Drug Resistance Workshop. Sitges, Spain.
40. Vermeiren H, van Craenenbroeck E, Alen P, et al. 2007. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods, 145:47-55.